Effect of extended-release quetiapine fumarate on quality of life and sleep in elderly patients with generalized anxiety disorder

Neuropsychiatry

Volumn 3, Issue 6, 2013, Pages 577-585

  Datto, Catherine ^a   Svedsäter, Henrik ^b   Locklear, Julie C ^a   Endicott, Jean ^c  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; QUETIAPINE;

AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT SATISFACTION; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SLEEP PARAMETERS; SLEEP QUALITY; SLEEP TIME;

EID: 84890317925     PISSN: 17582008     EISSN: 17582016     Source Type: Journal    
DOI: 10.2217/npy.13.77     Document Type: Article

References (29)

1. Carter RM, Wittchen HU, Pfister H, Kessler RC. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress. Anxiety 13(2), 78-88 (2001
2. Wittchen HU. Generalized anxiety disorder: Prevalence, burden, and cost to society. Depress. Anxiety 16(4), 162-171 (2002
3. Snyder AG, Stanley MA, Novy DM, Averill PM, Beck JG. Measures of depression in older adults with generalized anxiety disorder: A psychometric evaluation. Depress. Anxiety. 11(3), 114-120 (2000
4. Alwahhabi F. Anxiety symptoms and generalized anxiety disorder in the elderly: A review. Harv. Rev. Psychiatry 11(4), 180-193 (2003
5. Dell'Osso B, Camuri G, Benatti B, Buoli M, Altamura AC. Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: A study on patients with panic disorder, generalized anxiety disorder and obsessive-compulsive disorder. Early. Interv. Psychiatry doi:10.1111/eip.12016 (2013) (Epub ahead of print
6. Porensky EK, Dew MA, Karp JF et al. The burden of late-life generalized anxiety disorder: Effects on disability, health-related quality of life, and healthcare utilization. Am. J. Geriatr. Psychiatry 17(6), 473-482 (2009
7. Brenes GA, Miller ME, Stanley MA, Williamson JD, Knudson M, McCall WV. Insomnia in older adults with generalized anxiety disorder. Am. J. Geriatr. Psychiatry 17(6), 465-472 (2009
8. Bandelow B, Chouinard G, Bobes J et al. Extended-release quetiapine fumarate (quetiapine XR): A once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int. J. Neuropsychopharmacol. 13(3), 305-320 (2010
9. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 31(4), 418-428 (2011
10. Merideth C, Cutler A, She F, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: A randomized, placebo-controlled and active-controlled study. Int. Clin. Psychopharmacol. 27(1), 40-54 (2012
11. Mezhebovsky I, Magi K, She F, Datto C, Eriksson H. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int. J. Geriatr. Psychiatry 28(6), 615-625 (2013
12. Bortnick B, El-Khalili N, Banov M et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study. J. Affect. Disord. 128(1-2), 83-94 (2011
13. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Åström M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: A placebo- and duloxetine-controlled study. J. Clin. Psychiatry 70(4), 526-539 (2009
14. Endicott J, Paulsson B, Gustafsson U, Schiöler H, Hassan M. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep. J. Affect. Disord. 111(2-3), 306-319 (2008
15. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H. Extended release quetiapine fumarate monotherapy for major depressive disorder: Results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 14(6), 299-313 (2009
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. American Psychiatric Association, DC, USA (2000
17. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacol. Bull. 29(2), 321-326 (1993
18. Buysse DJ, Reynolds C 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 28(2), 193-213 (1989
19. Wyrwich K, Harnam N, Revicki DA, Locklear JC, Svedsater H, Endicott J. Assessing health-related quality of life in generalized anxiety disorder using the Quality Of Life Enjoyment and Satisfaction Questionnaire. Int. Clin. Psychopharmacol. 24(6), 289-295 (2009
20. Wetherell JL, Le Roux H, Gatz M. DSM-IV criteria for generalized anxiety disorder in older adults: Distinguishing the worried from the well. Psychol. Aging 18(3), 622-627 (2003
21. Cochen V, Arbus C, Soto ME et al. Sleep disorders and their impacts on healthy, dependent, and frail older adults. J. Nutr. Health Aging 13(4), 322-329 (2009
22. Baldwin SH, Anderson IM, Nutt DJ et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 19(6), 567-596 (2005
23. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J. Biol. Psychiatry 9(4), 248-312 (2008
24. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can. J. Psychiatry 51(10), S9-S91 (2006
25. Allgulander C, Jorgensen T, Wade A et al. Health-related quality of life (HRQOL) among patients with generalised anxiety disorder: Evaluation conducted alongside an escitalopram relapse prevention trial. Curr. Med. Res. Opin. 23(10), 2543-2549 (2007
26. Demyttenaere K, Andersen HF, Reines EH. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. Int. Clin. Psychopharmacol. 23(5), 276-286 (2008
27. Endicott J, Russell JM, Raskin J et al. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: Three independent studies. J. Clin. Psychiatry 68(4), 518-524 (2007
28. Buoli M, Caldiroli A, Caletti E, Paoli RA, Altamura AC. New approaches to the pharmacological management of generalized anxiety disorder. Expert Opin. Pharmacother. 14(2), 175-184 (2013
29. Ensrud KE, Blackwell TL, Ancoli-Israel S et al. Use of selective serotonin reuptake inhibitors and sleep disturbances in community-dwelling older women. J. Am. Geriatr. Soc. 54(10), 1508-1515 (2006